Pfizer's Anti-PD-1 Bladder Cancer Treatment

This is a news story, published by Yahoo, that relates primarily to Pfizer news.

drug discoveries news

For more drug discoveries news, you can click here:

more drug discoveries news

Yahoo news

For more news from Yahoo, you can click here:

more news from Yahoo

About the Otherweb

Otherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best health news, business news, entertainment news, and much more. If you like drug discoveries news, you might also like this article about

bladder cancer

. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest BCG vaccine news, bladder cancer cases news, drug discoveries news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!

antibody treatment

Reuters

•

Pfizer's bladder cancer therapy meets main goal in late-stage study

Summary

Nutrition label

81% Informative

Pfizer 's experimental treatment for a type of bladder cancer significantly improved the time patients remained free of certain complications, including cancer recurrence.

Pfizer said it plans to present the data at an upcoming medical meeting and discuss it with global health regulators for a potential approval.

The drug is an anti-PD-1 monoclonal antibody, the same class of treatment as Merck 's Keytruda .

VR Score

Informative language

Neutral language

Article tone

formal

Language

English

Language complexity

Offensive language

possibly offensive